

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: left;">Complete If Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>09/974,519</td> </tr> <tr> <td>Filing Date</td> <td>October 10, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Thakker et al.</td> </tr> <tr> <td>Art Unit</td> <td>1612</td> </tr> <tr> <td>Examiner Name</td> <td>Benjamin Packard</td> </tr> <tr> <td>Attorney Docket Number</td> <td>421/32/2</td> </tr> </table>		Complete If Known		Application Number	09/974,519	Filing Date	October 10, 2001	First Named Inventor	Thakker et al.	Art Unit	1612	Examiner Name	Benjamin Packard	Attorney Docket Number	421/32/2
Complete If Known																	
Application Number	09/974,519																
Filing Date	October 10, 2001																
First Named Inventor	Thakker et al.																
Art Unit	1612																
Examiner Name	Benjamin Packard																
Attorney Docket Number	421/32/2																
Sheet	1	of	1														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Barros, F., et al., <i>Modulation of human erg K⁺ channel gating by activation of a G protein coupled receptor and protein kinase C</i> . <u>The Journal of Physiology</u> . Vol. 511, No. 2 pgs.:333-346 (1998).	
	2	Official Action corresponding to Canadian Patent Application No. 2,425,215 dated May 22, 2008.	
	3	Official Action corresponding to European Patent Application No. 06 119 516 0 - 1223 dated December 9, 2008.	
	4	Polascik, T., et al., <i>Neomycin cannot be used as a selective inhibitor of inositol phospholipid hydrolysis in intact or semi-permeabilized human platelets</i> . <u>Biochemical Journal</u> . Vol. 243 pgs.:815-819 (1987).	
	5	Sipma et al., <i>Neomycin inhibits histamine and thapsigargin mediated Ca²⁺ entry in DDT₁MF-2 cells independent of phospholipase C activation</i> . <u>European Journal of Pharmacology</u> . Vol. 305, No. 1-3 pgs.:207-212 (1996).	
	6	Van Itallie, C.M., and Anderson, J.M., <i>Claudins and Epithelial Paracellular Transport</i> . <u>Annual Review of Physiology</u> . Vol. 68 pgs.:403-429 (2006).	
	7	Van Itallie, C.M., and Anderson, J.M., <i>The Molecular Physiology of Tight Junction Press</i> . <u>Physiology</u> . Vol. 19 pgs.:331-338 (2004).	
	8	Ward et al., <i>Role of Phospholipase C-β in the Modulation of Epithelial Tight Junction Permeability</i> . <u>The Journal of Pharmacology and Experimental Therapeutics</u> . Vol. 304 pgs.:689-698 (2003).	
	9	Yeaman et al., <i>Polarity of TRH receptors in transfected MDCK cells is independent of endocytosis signals and G protein coupling</i> . <u>American Journal of Physiology</u> . Vol. 270 pgs.:C753-C762 (1996).	

Examiner Signature	/Benjamin Packard/	Date Considered	03/31/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 †Applicant's unique citation designation number (optional). ‡Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.P./